MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
AOD-9604 + CJC-1295 + Ipamorelin Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
This research-protocol stack combines AOD-9604 (a synthetic hGH lipolytic fragment that activates beta-3 adrenergic lipolysis in adipocytes) with two growth-hormone secretagogues — CJC-1295 (a long-acting GHRH analogue) and ipamorelin (a selective ghrelin-receptor / GHSR-1a agonist). The mechanistic rationale is complementary: AOD-9604 stimulates direct adipocyte lipolysis without engaging the GH receptor [1], while CJC-1295 and ipamorelin amplify endogenous pulsatile GH secretion through the GHRH and ghrelin axes respectively [2][3]. No randomized clinical trial has ever tested this three-peptide combination; all efficacy claims are extrapolated from individual-component pharmacology studies. None of the three components is FDA approved as a drug — AOD-9604 holds GRAS food-ingredient status only, while CJC-1295 and ipamorelin have no regulatory approval anywhere. The stack is research-chemical only.
Reconstitute: Add 3 mL bacteriostatic water → 4 mg/mL concentration.
Easy measuring: At 4 mg/mL, 1 unit = 0.01 mL = 0.0400 mg (40 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Regulatory status: No component is FDA approved as a drug. AOD-9604 has GRAS food-ingredient status; CJC-1295 and ipamorelin have no regulatory approval. Combination is sold strictly for laboratory use.
Evidence base: Zero randomized trials of the combination. AOD-9604 monotherapy delivered only 1.8 kg placebo-subtracted weight loss at 12 weeks; the GH-secretagogue arm has no controlled body-composition trial data [1].
GH-axis concerns: Sustained CJC-1295 + ipamorelin use carries theoretical concerns shared with exogenous GH: glucose intolerance, water retention, carpal tunnel syndrome and IGF-1-mediated oncogenic risk — none formally characterized in long-cycle protocols.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
Interactive AOD-9604 + CJC-1295 + Ipamorelin Syringe Calculator
Currently visualizing the 12 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 12mg dry powder in 3mL water yields 4.00 mg/mL. To evaluate a 250mcg dose, pull to 6.3 units (6 syringe ticks).
U-100 Syringe Representation
6.3 Units (6 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose | Units (mL) |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3–12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 12 mg vial.
Peptide Blend Vials (12 mg each):
- check8 weeks (~11.2 mL total): 4 vials
- check12 weeks (~16.8 mL total): 6 vials
- check16 weeks (~22.4 mL total): 8 vials
Insulin Syringes (U‑100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- check16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
The three components operate on distinct molecular pathways that converge on fat mobilization and growth-hormone-axis activation. AOD-9604 reproduces the C-terminal lipolytic domain of human growth hormone (residues 176–191) and acts via beta-3 adrenergic receptor signaling in adipocytes, increasing hormone-sensitive lipase activity and triglyceride hydrolysis without engaging the GH receptor itself [1]. Its half-life is short (15–30 minutes) and daily dosing is required to maintain effect. The peptide does not increase IGF-1 and does not affect glucose homeostasis or insulin sensitivity. CJC-1295 is a synthetic 30-amino-acid analogue of GHRH (growth-hormone-releasing hormone) modified at positions 2, 8, 15 and 27 to resist enzymatic degradation. The 'no-DAC' version has a half-life of approximately 30 minutes and produces a single GH pulse; the 'DAC' (drug-affinity-complex) version uses an albumin-binding moiety to extend half-life to 6–8 days, producing sustained elevation of basal GH and IGF-1 over 9–11 days [2]. Ipamorelin is a pentapeptide selective agonist at the growth-hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) in the anterior pituitary. Unlike older GH secretagogues (GHRP-2, GHRP-6, hexarelin), ipamorelin produces a clean GH pulse without elevating cortisol, prolactin or ACTH, and without stimulating appetite via the ghrelin orexigenic pathway. Half-life is approximately 2 hours [3]. The conventional pharmacologic rationale for combining a GHRH analogue with a ghrelin-receptor agonist is mechanistic synergy: GHRH amplifies pituitary GH-cell sensitivity to depolarization while ghrelin-receptor agonism drives the depolarization itself, producing GH pulses that are larger than either drug alone — a phenomenon documented in non-stack pharmacology trials with sermorelin + GHRP-2 [3]. Administration is via daily subcutaneous injection. The most common protocol uses AOD-9604 in the morning on an empty stomach (250–500 mcg SC), and CJC-1295 (no-DAC) + ipamorelin co-administered before bed (100–200 mcg each SC) to align the synthetic GH pulse with the natural slow-wave-sleep pulse. Some protocols use CJC-1295 DAC twice weekly instead of daily no-DAC. The cycle length is typically 8–12 weeks followed by 4–8 weeks of washout, after which pituitary responsiveness to secretagogue stimulation typically recovers. Downstream effects expected from this combination include modest fat-mass reduction (driven primarily by AOD-9604 and amplified by GH-mediated lipolysis), improved sleep quality and recovery (driven by elevated GH and IGF-1), and potential lean-tissue preservation during caloric deficit. Critically, none of the claimed synergy between these three peptides has been tested in a randomized controlled trial; the rationale is mechanistic and the dosing protocols are extrapolated from individual-peptide research.
Clinical Trial Efficacy Highlights
- starNo randomized clinical trial has tested the AOD-9604 + CJC-1295 + Ipamorelin combination. All efficacy claims are extrapolated from individual-peptide research, primarily the AOD-9604 Phase 2 obesity trial (placebo-subtracted 1.8 kg at 12 weeks) [1] and GH secretagogue pharmacology studies showing 2–10-fold elevation of plasma GH with CJC-1295 + ipamorelin co-administration [2][3].
- starAOD-9604 Phase 2 12-week trial in ~300 obese adults showed placebo-subtracted weight loss of 1.8 kg on 1 mg/day SC; 23-week follow-up reproduced this modest effect. No interaction with GH secretagogues was tested in any published study [1].
- starCJC-1295 DAC pharmacology trials demonstrated 2–10-fold increases in plasma GH for 6 days following a single 250-mcg/kg SC dose, and 0.5–3-fold increases in IGF-1 lasting 9–11 days — the longest-duration GH stimulation reported for any synthetic GHRH analogue [2].
- starIpamorelin Phase 1 pharmacology trials in healthy adults showed approximately 5–8-fold GH peak elevations within 60 minutes of subcutaneous administration, without measurable changes in cortisol, prolactin, ACTH, glucose or appetite — establishing the selectivity profile that distinguishes it from older GHRPs [3].
- starA small open-label study of sermorelin + GHRP-2 co-administration (mechanistically analogous to CJC-1295 + ipamorelin) showed synergistic GH release approximately 2–3-fold greater than either drug alone — supporting the dual-secretagogue stacking concept [3].
- starNo published data on the effect of combined GH-secretagogue therapy on adipose-tissue mass, body composition, or weight loss in humans exists; the lean-tissue and fat-loss claims for this stack are entirely mechanistic extrapolation.
- starReal-world observational data from compounding clinics and wellness practitioners (not peer-reviewed) report subjective improvements in sleep quality, recovery and modest body-composition change, but no controlled efficacy data.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningAOD-9604 across six clinical trials showed a placebo-equivalent safety profile with no observed effects on glucose, IGF-1 or cardiovascular markers; primary adverse events were mild injection-site reactions in 5–10% [1].
- warningCJC-1295 DAC has been associated in scattered case reports with sustained mild elevations in heart rate (3–5 bpm) and transient mild flushing — likely driven by extended GH/IGF-1 elevation rather than direct cardiovascular effect [2].
- warningSustained GH-axis activation from chronic CJC-1295 + ipamorelin therapy theoretically raises the same long-term concerns as exogenous GH therapy: water retention, peripheral edema, carpal tunnel syndrome, and arthralgia. These have not been formally characterized in trials but are commonly reported anecdotally with long-cycle protocols.
- warningIpamorelin is selective for the GHSR but stimulation of ghrelin-receptor signaling may produce mild post-injection flushing or sensation of warmth in 5–10% of users; appetite stimulation is uncommon due to its selectivity profile.
- warningIncreased IGF-1 from sustained GH elevation raises theoretical oncogenic concerns — IGF-1 has mitogenic effects on multiple tumor types and high-normal IGF-1 levels are associated with increased risk of several cancers in epidemiologic studies. Long-term safety of synthetic GH-axis stimulation is not characterized.
- warningGlucose intolerance, well-documented with exogenous GH therapy, is a theoretical concern with chronic CJC-1295 + ipamorelin protocols. Periodic monitoring of fasting glucose and HbA1c is reasonable for any extended cycle.
- warningInjection-site reactions occur in approximately 5–10% of users across all three peptides, generally mild and self-limited with site rotation. Daily multi-injection protocols may amplify cumulative site irritation.
- warningQuality control of compounded or research-chemical supply remains the dominant practical safety concern: identity, purity, sterility and contamination of commercial supply are highly variable and not regulated to pharmaceutical standards.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical AOD-9604 + CJC-1295 + Ipamorelin dosage?expand_more
Common research protocols: AOD-9604 250–500 mcg SC in the morning on an empty stomach; CJC-1295 (no-DAC) 100–200 mcg SC pre-bed; Ipamorelin 100–200 mcg SC pre-bed. Cycle is 8–12 weeks followed by 4–8 weeks washout. Some users substitute CJC-1295 DAC at 1–2 mg twice weekly instead of daily no-DAC. No randomized trial has validated any of these doses.
How is this stack different from Semaglutide?expand_more
Semaglutide is an FDA-approved GLP-1 receptor agonist with robust randomized-trial data showing ~15% weight loss. This stack combines three research-chemical peptides with no controlled-trial data for the combination. The mechanism (lipolysis + GH-axis stimulation) is fundamentally different from incretin therapy and the expected efficacy is much smaller (~2–3 kg from AOD-9604 component alone).
What are the most common side effects of this stack?expand_more
Most common are mild injection-site reactions (5–10%) and occasional water retention or mild flushing from the GH-axis component. Theoretical concerns include glucose intolerance from sustained GH elevation, peripheral edema, carpal tunnel syndrome, and oncogenic concerns from chronic IGF-1 elevation. No controlled-trial safety data for the combination [1][2].
How should this stack be reconstituted and stored?expand_more
Each peptide is reconstituted separately with bacteriostatic water (typically 2 mL per 5 mg vial). Store at 2–8 C, protect from light, use within 28 days. Separate injections in the morning (AOD-9604) and pre-bed (CJC-1295 + ipamorelin) prevent peptide interaction in solution. Do not freeze. Some protocols draw both pre-bed peptides into a single syringe for a single injection.
Is this stack FDA approved?expand_more
No. None of the three components is FDA approved as a drug. AOD-9604 holds FDA GRAS status as a food ingredient only. CJC-1295 and ipamorelin have no regulatory approval anywhere. The combination is sold by research-chemical suppliers strictly for laboratory use and is not legally available for human therapeutic use. Some US compounding pharmacies have offered them under physician oversight.
Academic References & Study Citations
Heffernan M, Summers RJ, Thorburn A, et al. (2001) Endocrinology 142:5182-5189. 'The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice'. View Scientific Paper →
Teichman SL, Neale A, Lawrence B, et al. (2006) J Clin Endocrinol Metab 91:799-805. 'Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults'. View Scientific Paper →
Raun K, Hansen BS, Johansen NL, et al. (1998) Eur J Endocrinol 139:552-561. 'Ipamorelin, the first selective growth hormone secretagogue'. View Scientific Paper →
Sigalos JT, Pastuszak AW. (2018) Sex Med Rev 6:45-53. 'The Safety and Efficacy of Growth Hormone Secretagogues' — comprehensive review. View Scientific Paper →
Stier H, Vos E, Kenley D. (2013) Regul Toxicol Pharmacol. 'Safety and tolerability of the hexadecapeptide AOD9604 in humans' — pooled safety analysis. View Scientific Paper →
Alba M, Fintini D, Sagazio A, et al. (2006) Endocrinology. 'Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog' — pharmacokinetics review. View Scientific Paper →
Ionescu M, Frohman LA. (2006) J Clin Endocrinol Metab 91:4792-4797. 'Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog'. View Scientific Paper →
FDA GRAS Notice GRN 525 (2014) — AOD-9604 Generally Recognized as Safe status for use as a food ingredient. View Scientific Paper →